• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS, LIMITED IMMULITE 2000 ESTRADIOL

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS, LIMITED IMMULITE 2000 ESTRADIOL Back to Search Results
Model Number IMMULITE 2000 ESTRADIOL
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem No Known Impact Or Consequence To Patient (2692)
Event Date 02/21/2017
Event Type  malfunction  
Manufacturer Narrative
The customer contacted a siemens customer care center (ccc) specialist.The customer is aware that the patient sample may have interference with the immulite 2000 xpi estradiol assay.The cause of the discordant, falsely elevated estradiol result on one patient sample is unknown.Siemens is investigating the issue.
 
Event Description
A discordant, falsely elevated estradiol result was obtained on one patient sample on an immulite 2000 xpi instrument, when using reagent lot 384.The sample was repeated on an alternate platform, resulting lower and matching the clinical picture of the patient.The initial result was not reported to the physician(s).The repeat result obtained on the alternate platform was reported to the physician(s).There are no reports of patient intervention or adverse health consequence due to the discordant, falsely elevated estradiol result.
 
Manufacturer Narrative
The initial mdr 2432235-2017-00272 was filed on april 20, 2017.Additional information (04/24/2017): the customer did not provide patient sample for further evaluation.A siemens headquarters support center (hsc) specialist reviewed the information provided by the customer.Quality controls and other patient samples were not affected.The hsc specialist stated that a non-specific interferent may have resulted in discordant result.The hsc specialist stated that immunoassays are subject to a number of interferences including those caused by endogenous antibodies.Interference can occur because of heterophile antibodies, anti-animal antibodies and auto antibodies.Patients exposed to animals or animal serum products can be prone to this interference and anomalous values may be observed.The interfering antibodies can give rise to a falsely elevated or less commonly a falsely low result.The discordant result in this scenario was inconsistent with the patient's clinical picture.The hsc specialist stated that the interferent may not necessarily be due to an interfering antibody but may be due to other exogenous interferences such as drugs, nutritional supplements and/or herbal medicine in the blood.The cause of the discordant, falsely elevated estradiol result on one patient sample is unknown.The device is performing within manufacturing specifications.No further evaluation of device is required.
 
Manufacturer Narrative
The initial mdr 2432235-2017-00272 was filed on 20-apr-2017.The first supplemental mdr 2432235-2017-00272_s1 was filed on 09-may-2017.Additional information (10-jan-2018): siemens received the patient sample from (b)(6) 2017 for in-house testing.The sample received from the customer was run on immulite 2000, advia centaur xp and dimension vista instruments.Based on the data, technical support laboratory (tsl) does not confirm a potential siemens product non-conformance with immulite 2000 e2 kit lot d393.The difference seen between immulite results from the customer versus tsl could potentially be due to sample or interferent degradation.Advia centaur and dimension vista estradiol assays use monoclonal antibodies and immulite uses rabbit polyclonal, and therefore can show different cross reactivity.The assay is performing within manufacturing specifications.No further evaluation of device is required.Updated with the results obtained during in-house testing.
 
Manufacturer Narrative
The initial mdr 2432235-2017-00272 was filed on 20-apr-2017.The first supplemental mdr 2432235-2017-00272_s1 was filed on 09-may-2017.The second supplemental mdr 2432235-2017-00472_s2 was filed on 06-feb-2018.Additional information (09-mar-2018): the customer stated that the patient was taking dasatinib at the time of the event which gave elevated estradiol results, greater than physician's expectations on the immulite 2000 instrument, while the results obtained on the alternate platform were in agreement with clinical expectation of the patient.A siemens headquarters support center (hsc) specialist reviewed the event data and the investigation results.The hsc specialist stated that the results generated upon in-house testing in siemens technical support laboratory confirmed findings of higher than expected estradiol levels on the immulite 2000 instrument.Dasatinib is a tyrosine kinase inhibitor antineoplastic agent.Dasatinib is not listed in the immulite 2000 estradiol instructions for use limitation section, testing has not been done and no claims exist.The patients dosing of dasatinib has remained constant but immulite estradiol results have dropped in recent draws.Data presented does not suggest that dasatinib is the cause of the elevated immulite estradiol results.Siemens is not aware of any similar incidents related to dasatinib and elevated estradiol results on the immulite.The discordant result is recognized as being inconsistent with the patient's clinical picture.For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.If the estradiol results are inconsistent with clinical evidence, additional testing is suggested to confirm the result.Based upon the information provided and reviewed during this investigation of an immulite 2000 estradiol, no product issue has been identified.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
IMMULITE 2000 ESTRADIOL
Type of Device
IMMULITE 2000 ESTRADIOL
Manufacturer (Section D)
SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS, LIMITED
registration #: 3002806944
glyn rhonwy
llanberis, gwynedd, LL55 4EL
UK  LL55 4EL
MDR Report Key6506956
MDR Text Key73231483
Report Number2432235-2017-00272
Device Sequence Number1
Product Code CHP
Combination Product (y/n)N
PMA/PMN Number
K932926
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional,u
Type of Report Initial,Followup,Followup,Followup
Report Date 04/03/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Model NumberIMMULITE 2000 ESTRADIOL
Device Catalogue NumberL2KE22
Device Lot Number384
Was Device Available for Evaluation? No
Was the Report Sent to FDA? No
Initial Date Manufacturer Received 03/29/2017
Initial Date FDA Received04/20/2017
Supplement Dates Manufacturer ReceivedNot provided
01/10/2018
03/09/2018
Supplement Dates FDA Received05/09/2017
02/06/2018
04/03/2018
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Age13 YR
-
-